For years, the UK's clinical research landscape held a frustrating truth: costing and contracting for commercial research needed to evolve if the nation was to remain an attractive option f
Lord James O’Shaughnessy has welcomed the UK government’s official response to his review of commercial clinical trials, saying there have been a number of positive develo
Biopharmaceutical companies across the globe are rapidly expanding their pipelines as they aim to break new ground in different disease areas, on behalf of patients awaiting life-changing t
